Breakthrough Science for Better Health

Passionately committed to bettering the lives of patients with cardiorenal diseases.
Learn About Us

THE FACTS

740,000 ESRD patients with hyperphosphatemia in major developed countries
~2 Million people in U.S. with CKD and/or heart failure have hyperkalemia
~90,000 people with ESRD die in the U.S. each year – a number higher than those with breast cancer, hepatitis C and HIV combined
~95% of ESRD patients need phosphate control
Impact

Making Better Medicine For Patients In Need

We are advancing our lead product, tenapanor, for the treatment of hyperphosphatemia in patients with CKD who are on dialysis.

Learn More About Our Tenapanor Programs

Everyone here is excited about what we’re creating and what it could mean for patients.

- Kelli, HR

Make An Impact With Us

PIPELINE

PROGRAM
INDICATION
RESEARCH
PHASE 1
PHASE 2
PHASE 3
MARKETED
Cardiorenal Programs
Tenapanor
ESRD Hyperphosphatemia
(NHE3 Inhibitor)
RDX011
Cardiorenal Indications
(NHE3 Inhibitor)
RDX013
Hyperkalemia
(Potassium Secretagogue)
Gastrointestinal Programs
Tenapanor
IBS-C
(NHE3 Inhibitor)
RDX011
GI Indications
(NHE3 Inhibitor)